DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Clinical trials for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested for Tough-to-Treat blood cancers
Disease control CompletedThis early-stage study tested a new drug called PRT2527, both by itself and combined with other cancer drugs, in people with advanced blood cancers that had returned or stopped responding to standard treatments. The main goals were to find a safe dose and see if the treatments sh…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Cancer patients get chance to continue promising drug in Long-Term safety study
Disease control CompletedThis study allowed patients with various cancers who had benefited from the drug tazemetostat in earlier trials to continue receiving it. The main goal was to monitor the drug's long-term safety in these patients. It was open to people who had not seen their cancer worsen and cou…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE1, PHASE2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Experimental drug shows early promise against tough blood cancers
Disease control CompletedThis first-in-human study tested a new drug called Purinostat Mesylate (PM) in 29 adults with advanced blood cancers that had returned or stopped responding to standard treatments. The main goals were to find a safe dose and see how the drug moves through the body. Early lab stud…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
New hope for Tough-to-Treat lymphoma: experimental combo aims to shrink tumors fast
Disease control CompletedThis study tested a new combination of drugs for people with an aggressive type of lymphoma (DLBCL) that had come back or stopped responding to their first treatment. The goal was to see if adding a new drug called glofitamab to a standard chemotherapy regimen could effectively s…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
Scientists look back to decode Lymphoma's genetic blueprint
Knowledge-focused CompletedThis study looked back at medical records and tissue samples from 555 adults with aggressive B-cell lymphomas. Researchers analyzed the genetic makeup of these cancers to see if specific genetic patterns, as defined by a 2017 classification system, are linked to how long patients…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Sponsor: Andrés José Maria Ferreri • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:19 UTC